Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Diffuse Large B-Cell Lymphoma: An Individual Patient–Level Analysis of Multiple Randomized Trials (SEAL)

PURPOSE: Overall survival (OS) is the definitive and best-established primary efficacy end point to evaluate diffuse large B-cell lymphoma (DLBCL) therapies, but it requires prolonged follow-up. An earlier end point assessed post-treatment would expedite clinical trial conduct and accelerate patient...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Oncol
Main Authors: Shi, Qian, Schmitz, Norbert, Ou, Fang-Shu, Dixon, Jesse G., Cunningham, David, Pfreundschuh, Michael, Seymour, John F., Jaeger, Ulrich, Habermann, Thomas M., Haioun, Corinne, Tilly, Hervé, Ghesquieres, Hervé, Merli, Francesco, Ziepert, Marita, Herbrecht, Raoul, Flament, Jocelyne, Fu, Tommy, Coiffier, Bertrand, Flowers, Christopher R.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2018
Assuntos:
ORIGINAL REPORTS
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6532366/
https://ncbi.nlm.nih.gov/pubmed/29975624
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2018.77.9124
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados